NanoViricides, Inc. (NYSE American: NNVC) announced a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants carry an exercise price of $1.75 per share and a three-year term, with closing expected on or about May 18, 2026, subject to customary conditions.
This capital raise comes as the company advances its clinical-stage, broad-spectrum antiviral drug NV-387, which has received Orphan Drug Designation from the U.S. FDA. The designation could provide seven years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. NV-387 is designed as a host-mimetic nanomedicine that viruses and their variants cannot escape, and has shown effectiveness in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.
The offering provides NanoViricides with additional funding to support its drug development programs. For investors, the transaction highlights the company's ongoing efforts to secure resources for its pipeline, while the participation of an institutional investor signals confidence in the company's approach. The broader implications for the industry include the potential for a new class of broad-spectrum antivirals that could address multiple viral threats, including those with pandemic potential.
For more details on the offering, the full press release is available at https://ibn.fm/Z8Etj. Additional news and updates on NanoViricides can be found at https://ibn.fm/NNVC.
